Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Speedy bug ID: new tests aim to cut antibiotic guesswork in ICU blood infections

NCT ID NCT05741424

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

This study tested whether three new diagnostic tools could help doctors pick the best antibiotic faster for ICU patients with Gram-negative bloodstream infections. Researchers compared standard lab methods to the new tests in 100 patients. The goal was to see if more patients got the right, narrowest antibiotic within 24 hours of a blood sample.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diagnostic tests (BacT/Alert VIRTUO, BioFire BCID2, REVEAL)
What this could lead to
If successful, this could show that using these advanced tests helps doctors pick the most effective antibiotic sooner, potentially improving patient outcomes in the ICU.
What could go wrong
This is a small, single-center study with only 100 patients, so results may not apply to all hospitals. The tests themselves don't treat the infection—they only guide treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Mar 2023

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient must be a member or beneficiary of a health insurance plan * Patient admitted to the ICU with at least one positive blood culture for Gram-negative bacteremia For the 'after' section of the study only: * Patient must have given their free and informed consent or included by emergency procedure * Patient signed the consent form or included by emergency procedure Exclusion Criteria: * The subject is participating in this study, or is in a period of exclusion determined by a previous study * Consent refusal * Patient with a polymicrobial blood culture * Patient with a second episode of bacteremia * Moribund patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacteremia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis gram-negative bacterial infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacteremia

Contacts and locations

Locations

  • CHU de Nîmes

    Nîmes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.